These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 19745023)

  • 1. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin and axonal Na+ channel function in vivo.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
    Park SB; Lin CS; Kiernan MC
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
    Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
    Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
    Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
    Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute changes in nerve excitability following oxaliplatin treatment in mice.
    Makker PGS; White D; Lees JG; Parmar J; Goldstein D; Park SB; Howells J; Moalem-Taylor G
    J Neurophysiol; 2020 Jul; 124(1):232-244. PubMed ID: 32519566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creatinine clearance rate and nerve conduction velocity are effective in objectively assessing oxaliplatin-neuropathy in patients with colorectal carcinoma.
    Hsu TW; Chen FA; Yao YH; Wang WS
    Hepatogastroenterology; 2012; 59(117):1441-5. PubMed ID: 22155857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
    Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
    Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish.
    Kiernan MC; Isbister GK; Lin CS; Burke D; Bostock H
    Ann Neurol; 2005 Mar; 57(3):339-48. PubMed ID: 15732107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
    Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
    Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
    Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.